Ilexgenin A

Research use only, not for human use.

Ilexgenin A is a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis MerrIlexgenin A (IA), a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr.treatment with IA attenuated atherosclerosis in high-fat diet-induced apolipoprotein E deficient mice via a series of effects involving regulation of lipid parameters, decrease of atherosclerosis-related indexes, inhibition of inflammatory cytokines secretion and pathological changes of main organs.?

Ilexgenin A is a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis MerrIlexgenin A (IA), a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr.treatment with IA attenuated atherosclerosis in high-fat diet-induced apolipoprotein E deficient mice via a series of effects involving regulation of lipid parameters, decrease of atherosclerosis-related indexes, inhibition of inflammatory cytokines secretion and pathological changes of main organs.?The underlying mechanism of IA was investigated on oxidized low-density lipoprotein (Ox-LDL)-induced THP-1 cells.?Pre-treatment with IA decreased active inflammation cytokines involving interleukin-6 (IL-6), IL-1 and tumor necrosis factor-α (TNF-α) expression in a concentration-dependent manner.IA inhibited the phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), IKKα phosphorylation and NF-κB activity induced by Ox-LDL.?Overall, these findings define IA as a novel drug candidate for anti-atherosclerotic therapy.(In Vitro):Ilexgenin A (0~100 μM; 24 hours; HT 29 and HCT 116 cells) effectively decreases cell viability in HT 29 and HCT 116 cells.Ilexgenin A (12.5~50 μM; 24 hours; HT 29 cells) downregulates the expression of SREBP-1, inhibits the translocation of SREBP-1 to the nucleus and decreases the content of TG.Ilexgenin A (12.5~50 μM; HT 29 and HCT 116 cells) induces cell cycle arrest at G1 phase in colon cancer cells.Ilexgenin A (12.5~50 μM; 24 hours; HCT 116 cells) modulates lipid metabolism. Ilexgenin A (50 μM; 24 hours; HT 29 and HCT 116 cells) regulates SREBP-1 by inhibiting HIF1α.Ilexgenin A inhibits fatty acids synthesis.(In Vivo):Ilexgenin A (20 mg/kg) ameliorates the AOM/DSS induced carcinogenesis. Ilexgenin A can regulate lipid metabolism. Ilexgenin A decreases the expression of SREBP-1 and HIF 1α in AOM/DSS mice.

Ilexgenin A (0~100 μM; 24 hours; HT 29 and HCT 116 cells) effectively decreases cell viability in HT 29 and HCT 116 cells.Ilexgenin A (12.5~50 μM; 24 hours; HT 29 cells) downregulates the expression of SREBP-1, inhibits the translocation of SREBP-1 to the nucleus and decreases the content of TG.Ilexgenin A (12.5~50 μM; HT 29 and HCT 116 cells) induces cell cycle arrest at G1 phase in colon cancer cells.Ilexgenin A (12.5~50 μM; 24 hours; HCT 116 cells) modulates lipid metabolism. Ilexgenin A (50 μM; 24 hours; HT 29 and HCT 116 cells) regulates SREBP-1 by inhibiting HIF1α.Ilexgenin A inhibits fatty acids synthesis. Cell Viability Assay Cell Line:HT 29 and HCT 116 cells Concentration:0~100 μM Incubation Time:24 hours Result:Effectively decreased cell viability in HT 29 and HCT 116 cells.Western Blot Analysis Cell Line:HT 29 cells Concentration:12.5~50 μMIncubation Time:24 hours Result:Downregulated the expression of SREBP-1. RT-PCRCell Line:HT 29 cells Concentration:12.5~50 μM Incubation Time:24 hours Result:Decreased the content of TG.Immunofluorescence Cell Line:HT 29 cells Concentration:12.5~50 μM Incubation Time:24 hours Result:Inhibited the translocation of SREBP-1 to the nucleus.

Ilexgenin A (20 mg/kg) ameliorates the AOM/DSS induced carcinogenesis. Ilexgenin A can regulate lipid metabolism. Ilexgenin A decreases the expression of SREBP-1 and HIF 1α in AOM/DSS mice.

——

Apoptosis

IL Receptor

IL Receptor|TNF-α

——

——

108524-94-3

502.69

C30H46O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (198.93 mM)

CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)C2C1(C)O)C)C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years